MichaelKnableDO

PubMed

• Putative psychosis genes in the prefrontal cortex: combined analysis of gene expression microarrays
  Kwang H. Choi, Michael Elashoff, Brandon W. Higgs, Jonathan Song, Sanghyeon Kim, Sarven Sabunciyan, Suad Diglisic, Robert H. Yolken, Michael B. Knable, E. Fuller Torre...> ;BMC Psychiatry. 2008 Nov 7
• A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia.
  Qiwen Mu, Kevin A. Johnson, Paul S. Morgan, Emily L. Grenesko, Christine Molnar, Berry Anderson, Ziad Nahas, F. Andrew Kozel, Samet Kose, Michael B. Knable, Prabhavath...> ;Schizophrenia Research. 2007 Aug 1
• A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia
  Mark S. George, Christine Molnar, Emily L. Grenesko, Berry Anderson, Qiwen Mu, Kevin A. Johnson, Ziad Nahas, Michael B. Knable, Prabhavathi B. Fernandes, Jorge L. Junc...> ;Schizophrenia Research. 2007 Jul 1
• Meta-analysis of 12 genomic studies in bipolar disorder.
  Michael Elashoff, Brandon W. Higgs, Robert H. Yolken, Michael B. Knable, Serge Weis, Maree J. Webster, Beata M. Barci, E. Fuller Torrey> ;Journal of Molecular Neuroscience. 2007 Jan 1
• Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts.
  C. Anthony Altar, Linda W. Jurata, Vinod Charles, Andrew L Lemire, Peng Liu, Yury V. Bukhman, Theresa A. Young, Jeffrey Bullard, Hiroko Yokoe, Maree J. Webster, Michae...> ;Biological Psychiatry. 2005 Jul 15
• Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains.
  E. Fuller Torrey, Beata M. Barci, Maree J. Webster, John J. Bartko, James H. Meador-Woodruff, Michael B. Knable> ;Biological Psychiatry. 2005 Feb 1
• Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium
  Michael B. Knable, Beata M. Barci, Maree J. Webster, James H. Meador-Woodruff, E F Torrey> ;Molecular Psychiatry. 2004 Jun 1
• Secretin for refractory schizophrenia.
  Brian B. Sheitman, Michael B. Knable, L. Fredrik Jarskog, Miranda Chakos, Leslie H. Boyce, John J. Early, Jeffrey A. Lieberman> ;Schizophrenia Research. 2004 Feb 1
• Central Muscarinic Acetylcholine Receptor Availability in Patients Treated with Clozapine
  Thomas J. Raedler, Michael B. Knable, Douglas W. Jones, Richard A Urbina, Michael F. Egan, Daniel R. Weinberger> ;Neuropsychopharmacology. 2003 Jun 11
• In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia.
  Thomas J Raedler, Michael B. Knable, Douglas W. Jones, Richard A Urbina, Julia G. Gorey, Kan S. Lee, Michael F. Egan, Richard Coppola, Daniel R. Weinberger> ;American Journal of Psychiatry. 2003 Jan 1
• Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series.
  Stefano Marenco, Michael F. Egan, Terry E. Goldberg, Michael B. Knable, Robert K. McClure, Georg Winterer, Daniel R. Weinberger> ;Schizophrenia Research. 2002 Oct 1
• Controlled trial of hydroxychloroquine in schizophrenia.
  Menelik Desta, Azeb Tadesse, Negussie Gebre, Beata M. Barci, E. Fuller Torrey, Michael B. Knable> ;Journal of Clinical Psychopharmacology. 2002 Oct 1
• Extract of Ginkgo biloba added to haloperidol was effective for positive symptoms in refractory schizophrenia.
  Michael Knable> ;Evidence-based Mental Health. 2002 Aug 1
• Relationship between cortisol and serotonin metabolites and transporters in alcolholism
  Andreas Heinz, Douglas W. Jones, Garth Bissette, Daniel W. Hommer, Paul W. Ragan, Michael B. Knable, Stefan Wellek, Markku Linnoila, Daniel R. Weinberger> ;Pharmacopsychiatry. 2002 Jul 1
• Test-Retest Stability of the Repeatable Battery for the Assessment of Neuropsychological Status in Schizophrenia
  Christopher M. Wilk, James M. Gold, John J. Bartko, Faith Dickerson, Wayne S. Fenton, Michael Knable, Christopher Randolph, Robert W. Buchanan> ;American Journal of Psychiatry. 2002 May 1
• Molecular abnormalities in the major psychiatric illnesses: Classification and Regression Tree (CRT) analysis of post-mortem prefrontal markers.
  Michael B. Knable, Beata M. Barci, John J Bartko, Maree J. Webster, E F Torrey> ;Molecular Psychiatry. 2002 Jan 1
• Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders.
  Maree J. Webster, Michael B. Knable, J. O'Grady, J. Orthmann, Cynthia Shannon Weickert> ;Molecular Psychiatry. 2002 Jan 1
• A Placebo-Controlled Trial of Omega-3 Fatty Acid (Ethyl Eicosapentaenoic Acid) Supplementation for Residual Symptoms and Cognitive Impairment in Schizophrenia
  Wayne S. Fenton, Faith Dickerson, John Boronow, Joseph R. Hibbeln, Michael B. Knable> ;American Journal of Psychiatry. 2001 Dec 1
• Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar d...
  Maree J. Webster, Michael B. Knable, N. Johnston-Wilson, K. Nagata, M. Inagaki, Robert H. Yolken> ;Brain Behavior and Immunity. 2001 Dec 1
• Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium.
  Michael B. Knable, E. Fuller Torrey, Maree J. Webster, John J Bartko> ;Brain Research Bulletin. 2001 Jul 15
• Topiramate for bulimia nervosa in epilepsy.
  Michael B. Knable> ;American Journal of Psychiatry. 2001 Feb 1
• Neuropharmacological studies with SPECT in neuropsychiatric disorders.
  Andreas Heinz, Douglas W. Jones, Thomas J Raedler, Richard Coppola, Michael B. Knable, Daniel R. Weinberger> ;Nuclear Medicine and Biology. 2000 Oct 1
• The Stanley Foundation brain collection and Neuropathology Consortium
  E. Fuller Torrey, Maree J. Webster, Michael B. Knable, N.L. Johnston, Robert H. Yolken> ;Schizophrenia Research. 2000 Aug 3
• Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder
  Thomas A. Bayer, M. Schramm, Nicole Feldmann, Michael B. Knable, Peter Falkai> ;Progress in Neuro-psychopharmacology & Biological Psychiatry. 2000 Aug 1
• In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia.
  Thomas J Raedler, Michael B. Knable, Douglas W. Jones, Todd Lafargue, Richard A Urbina, Michael F. Egan, David Pickar, Daniel R. Weinberger> ;Neuropsychopharmacology. 2000 Jul 1
• Join now to see all

Journal Articles

• William Whitney Godding and the concepts of asylum and therapeutic community  
  Knable MB, Psychiatric Annals, 1/1/2015
• The availability and effectiveness of residential treatment for persistent mental illness  
  Knable MB, Cantrell C, Vander Meer, Levine E, Psychiatric Annals, 1/1/2015
• Review of Karasu TB: Gotham Chronicles: The Culture of Sociopathy  
  Knable MB, Psychiatry, Interpersonal and Biological Processes, 1/1/2014
• Zonisamide for bipolar disorder, mania and mixed states: a randomized, double-blind, placebocontrolled, adjunctive trial  
  Dauphinais D, Knable M, Rosenthal J, Polanski M, Rosenthal N, Psychopharmacology Bulletin, 1/1/2011
• Zonisamide for bipolar depression: a randomized, double-blind, placebo-controlled, adjunctive trial  
  Dauphinais D, Knable M, Rosenthal J, Polanski M, Rosenthal N, Psychopharmacology Bulletin, 1/1/2011
• Meta-Analysis of 12 Genomic Studies in Bipolar Disorder  
  Elashoff M, Higgs BW, Yolken RH, Knable MB, Weis S, Webster MJ, Barci BM, Torrey EF, Journal of Molecular Neuroscience, 1/1/2007
• A single 20mg dose of dihdrexidine (DAR-0100), a full dopamine D1 agonist, is safe and well-tolerated in patients with schizophrenia  
  George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable MB, Fernandes P, Juncos J, Huang X, Nichols D, Mailman RB, Schizophrenia Research, 1/1/2007
• A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia  
  Mu Q, Johnson K, Morgan PS, Gernesko EL, Molnar CE, Anderson B, Nahas Z, Kozel FA, Kose S, Knable M, Fernandes P, Nichols DE, Mailman RB, George MS, Schizophrenia Research, 1/1/2007
• Neurochemical markers for schizophrenia, bipolar disorder and major depression in post-mortem brains  
  Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, Knable MB, Biological Psychiatry, 1/1/2005
• Deficient expression of proteosome, ubiquitin, and mitochondrial genes in hippocampal neurons of multiple schizophrenic patient groups  
  Altar CA, Jurata LW, Charles V, Lemire A, Liu P, Bukhman Y, Young TA, Bullard J, Yokoe H, Webster MJ, Knable MB, Brockman JA, Biological Psychiatry, 1/1/2005
• Secretin for refractory schizophrenia  
  Sheitman BB, Knable MB, Jarskog LF, Chakos M, Boyce LH, Early J, Lieberman JA, Schizophrenia Research, 1/1/2004
• Molecular abnormalities of the hippocampus in severe mental illness: post-mortem findings from the Stanley Neuropathology Consortium  
  Knable MB, Barci BM, Webster MJ, Meador-Woodruff J, Torrey EF, Molecular Psychiatry, 1/1/2004
• In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia  
  Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS, Egan MF, Coppola R, Weinberger DR, American Journal of Psychiatry, 1/1/2003
• Dr Fenton and colleagues reply  
  Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable MB, American Journal of Psychiatry, 1/1/2003
• Molecular abnormalities in the major psychiatric illnesses: classification and regression tree (CART) analysis of post-mortem prefrontal markers  
  Knable MB, Barci BM, Bartko JJ, Webster MJ, Torrey EF, Molecular Psychiatry, 1/1/2002
• Test-retest stability of the repeatable battery for the assessment of neuropsychological status in schizophrenia  
  Wilk CM, Gold JM, Bartko JJ, Dickerson F, Boronow J, Fenton WS, Knable MB, Randolph C, American Journal of Psychiatry, 1/1/2002
• Relationship between cortisol and serotonin metabolites and transporters in alcoholism  
  Heinz A, Jones DW, Bissette G, Hommer D, Ragan P, Knable M, Wellek S, Linnoila M, Weinberger DR, Pharmacopsychiatry, 1/1/2002
• Preliminary experience with an Ampakine (CX-516) as a single agent for the treatment of schizophrenia: a case series  
  Marenco S, Egan MF, Goldberg T, Knable MB, McClure R, Winterer G, Weinberger DR, Schizophrenia Research, 1/1/2002
• A controlled trial of hydroxychloroquine in schizophrenia  
  Desta M, Tadesse A, Gebre N, Barci BM, Torrey EF, Knable MB, Journal of Clinical Psychopharmacology, 1/1/2002
• Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders  
  Webster MJ, Knable MB, O'Grady J, Orthmann J, Shannon-Weickert C, Molecular Psychiatry, 1/1/2002
• Abnormalities of the cingulate gyrus in bipolar disorder and other severe psychiatric illness: Post-mortem findings from the Stanley Foundation Neuropathology Consorti...  
  Knable MB, Barci BM, Bartko JJ, Webster MJ, Torrey EF, Clinical Neuroscience Research, 1/1/2002
• Commentary on: A double-blind, placebo-controlled trial of extract of Gingko biloba added to haloperidol in treatment-resistant patients with schizophrenia (Zhang et a...  
  Knable MB, Evidence-Based Mental Health, 1/1/2002
• Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium  
  Knable MB, Torrey EF, Webster MJ, Bartko JJ, Brain Research Bulletin, 1/1/2001
• Placebo-controlled trial of omega-3 fatty acid (EPA) supplementation for residual symptoms and cognitive impairment in schizophrenia  
  Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable MB, American Journal of Psychiatry, 1/1/2001
• Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar d...  
  Webster MJ, Knable MB, Johnston-Wilson N, Inagaki M, Nagata K, Yolken RH, Brain, Behavior, and Immunity, 1/1/2001
• Join now to see all

Books/Book Chapters

• Conn's Current Therapy 
  Chapter: Schizophrenia 
  Page 1169 - 1171Knable MBEditors: Rakel RE, Bope ET.Saunders, Philadelphia2004
• The Post-Mortem Brain in Psychiatric Research 
  Chapter: Summary of prefrontal molecular abnormalities in the Stanley Foundation Neuropathology Consortium 
  Page 105 - 137Knable MB, Barci BM, Webster MJ, Torrey EFEditors: Agam G, Everall I, Belmaker RH.Kluwer Academic Publishers, Boston2002
• Surviving Manic-Depressive Illness: A Manual for Families, Consumers, and Providers 
  Torrey EF, Knable MBBasic Books, New York2002
• Psychiatry 
  Chapter: Pathophysiological basis of psychiatric disorders: focus on mood disorders and schizophrenia 
  Page 258 - 311Nemeroff CB, Musselman DL, Nathan KI, Schatzberg AF, Knable MB, Kleinman JE, Weinberger DR, Kilts CD, Weiss JMEditors: Tasman A, Kay J, Lieberman JA.Saunders, Philadelphia1997
• American Psychiatric Press Textbook of Psychopharmacology 
  Chapter: Neurobiology of schizophrenia 
  Page 479 - 499Knable MB, Kleinman JE, Weinberger DREditors: Schatzberg AF and Nemeroff CB.American Psychiatric Press, Washington, D.C.1995
• Join now to see all

Other

• Clozapine for Treating Schizophrenia. A Comparison of the States 
  Torrey EF, Knable MB, Quanbeck C, Davis JM, Treatment Advocacy Center
  http://tacreports.org/storage/documents/clozapine-for-treating-schizophrenia.pdf
  1/1/2015
• Missions impossible: The ongoing failure of NIMH to support sufficient research on severe mental disorders. 
  Torrey EF, Gottesman IG, Davis JM, Knable MB, Zdanowicz MT, Treatment Advocacy Center
  www.psychlaws.org
  Arlington, VA - 1/1/2000
• A mission forgotten: The failure of the National Institute of Mental Health to do sufficient research on severe mental illnesses 
  Torrey EF, Knable MB, Davis JM, Gottesman II, Flynn LM, National Alliance of the Mentally Ill
  www.nami.org
  Arlington, VA - 1/1/1999